- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about EBS
Recent news which mentions EBS
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
Johnson & Johnson's COVID-19 Shot Wins Its First Full Approval In Canada
November 24, 2021
From Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
November 08, 2021
From Benzinga
92 Biggest Movers From Friday
November 08, 2021
From Benzinga
See Why Emergent BioSolutions Stock Plunged 37% On Friday?
November 05, 2021
From Benzinga
Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher
November 05, 2021
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 05, 2021
From Benzinga
From Benzinga
64 Stocks Moving In Friday's Mid-Day Session
November 05, 2021
From Benzinga
Why Emergent Biosolutions Stock Is Crashing Today
November 05, 2021
From Motley Fool
Pfizer’s positive antiviral news raises hopes for a new easy-to-take treatment for COVID-19, and cases start to rise again in California
November 05, 2021
From MarketWatch
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
November 05, 2021
From Benzinga
A jog down memory lane shows the factor that mattered most to driving stocks — and it sure wasn’t interest rates
November 05, 2021
From MarketWatch
Emergent BioSolutions inc (EBS) Q3 2021 Earnings Call Transcript
November 05, 2021
Tickers
EBS
From Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
November 04, 2021
From Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
From Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
From Motley Fool
From Benzinga
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
October 15, 2021
From Benzinga
5 Value Stocks To Watch In The Healthcare Sector
October 11, 2021
From Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
From Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
From Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
From Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
From Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
September 22, 2021
From Benzinga
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate
September 14, 2021
Tickers
EBS
From Benzinga
8 F-Rated Stocks to Sell in September
September 10, 2021
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.